How much funding has Artios Pharma raised?

Artios Pharma has raised $237.0M in total funding, most recently a Series C round.

Who are Artios Pharma's investors?

Artios Pharma's investors include Omega Funds, TCGX, Andera Partners, LSP Life Sciences Partners, Sofinnova Partners, Avidity Partners.

When was Artios Pharma founded?

Artios Pharma was founded in 2016.

Where is Artios Pharma headquartered?

Artios Pharma is headquartered in Cambridge.

What industry is Artios Pharma in?

Artios Pharma operates in Biotech, Healthcare.

How many employees does Artios Pharma have?

Artios Pharma has 51-200 employees.

Artios Pharma

Cambridge · Founded 2016 · $237.0M raised

Biotech

Healthcare

Headquarters: Cambridge
Employees: 51–200
Founded: 2016
Business Model: B2B

Website: artiospharma.com
Total Funding: $237.0M
Last Round: $153.0M Series CJan 2021
Rounds: 2

About

Artios Pharma is a clinical-stage oncology company developing novel cancer therapies that exploit DNA Damage Response (DDR) and repair pathways leveraged by cancer cells to promote survival. Founded in 2016 and headquartered in Cambridge, UK, Artios has built a pipeline of first-in-class and best-in-class DDR inhibitors, including its lead program alnodesertib in Phase 2 trials for ATM-deficient pancreatic and colorectal cancers. The company raised $115 million in a Series D in November 2025 to advance its clinical programs.

Summary

Artios Pharma is a Biotech company based in Cambridge, founded in 2016. It has raised $237.0M in total across 2 rounds, most recently a $153.0M Series C round in Jan 2021. Investors include Omega Funds, TCGX and Andera Partners.